D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 72 Citations 16,105 195 World Ranking 4008 National Ranking 2022

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Enzyme
  • Internal medicine

His main research concerns Plasminogen activator, Molecular biology, Plasminogen activator inhibitor-1, Biochemistry and Vitronectin. His Plasminogen activator research incorporates themes from Serpin, Neuroserpin, Ischemia and Tissue plasminogen activator. His Tissue plasminogen activator study incorporates themes from Familial encephalopathy with neuroserpin inclusion bodies and Cell biology.

His biological study spans a wide range of topics, including Endothelial stem cell, Plasminogen Inactivators, Integrin, Fibrinolysis and Endothelium. His study in Plasminogen activator inhibitor-1 is interdisciplinary in nature, drawing from both Cell adhesion, Reactive center and Binding site. His work carried out in the field of Vitronectin brings together such families of science as Cell migration, Angiogenesis and Plasmin.

His most cited work include:

  • The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. (619 citations)
  • Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein (476 citations)
  • Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. (403 citations)

What are the main themes of his work throughout his whole career to date?

Plasminogen activator, Plasminogen activator inhibitor-1, Biochemistry, Vitronectin and Molecular biology are his primary areas of study. His Plasminogen activator research integrates issues from Fibrinolysis, Tissue plasminogen activator and Serpin. His Plasminogen activator inhibitor-1 research is multidisciplinary, relying on both Cancer research, Plasmin, Binding site, Reactive center and In vivo.

His Mutant, Protease, Proteases and Serine study in the realm of Biochemistry connects with subjects such as Covalent bond. His Vitronectin research is multidisciplinary, incorporating perspectives in Angiogenesis, Cell adhesion and Small molecule. His Molecular biology research includes themes of Plasminogen Inactivators, Peptide sequence and Recombinant DNA.

He most often published in these fields:

  • Plasminogen activator (48.83%)
  • Plasminogen activator inhibitor-1 (36.62%)
  • Biochemistry (24.41%)

What were the highlights of his more recent work (between 2012-2021)?

  • Plasminogen activator (48.83%)
  • Plasminogen activator inhibitor-1 (36.62%)
  • Tissue plasminogen activator (14.08%)

In recent papers he was focusing on the following fields of study:

Daniel A. Lawrence mainly focuses on Plasminogen activator, Plasminogen activator inhibitor-1, Tissue plasminogen activator, Pharmacology and Internal medicine. His research in Plasminogen activator intersects with topics in Ex vivo, Serpin, Fibrin, Fibrinolysis and Thrombosis. His Serpin study is concerned with Biochemistry in general.

His Plasminogen activator inhibitor-1 study combines topics in areas such as Biophysics, Vitronectin, Plasmin and Urokinase. His studies deal with areas such as Inflammation, Neuroserpin, Stroke, Genetically modified mouse and Cell type as well as Tissue plasminogen activator. His Internal medicine study combines topics from a wide range of disciplines, such as Pathology, Endocrinology, Flow cytometry and Cardiology.

Between 2012 and 2021, his most popular works were:

  • Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects (38 citations)
  • Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke. (37 citations)
  • Plasminogen Activator Inhibitor-1 Inhibits Angiogenic Signaling by Uncoupling Vascular Endothelial Growth Factor Receptor-2-αVβ3 Integrin Cross Talk (34 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Enzyme
  • Internal medicine

His primary scientific interests are in Plasminogen activator, Blood–brain barrier, Tissue plasminogen activator, Pharmacology and Immunology. His research on Plasminogen activator focuses in particular on Plasminogen activator inhibitor-1. His Plasminogen activator inhibitor-1 study integrates concerns from other disciplines, such as Proteases, Serpin, Biochemistry, Venous thrombosis and Vitronectin.

Daniel A. Lawrence has researched Blood–brain barrier in several fields, including Neuroprotection and Pathology. His Pathology study deals with Internal medicine intersecting with Ex vivo and Endocrinology. His research in Tissue plasminogen activator focuses on subjects like Stroke, which are connected to Transplantation, LRP1, Integrin alpha M and Randomized controlled trial.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.

Steingrimur Stefansson;Daniel A. Lawrence.
Nature (1996)

804 Citations

Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein

Manuel Yepes;Maria Sandkvist;Elizabeth G. Moore;Thomas H. Bugge.
Journal of Clinical Investigation (2003)

627 Citations

Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.

J A van Mourik;D A Lawrence;D J Loskutoff.
Journal of Biological Chemistry (1984)

569 Citations

Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.

Tor Ny;M Sawdey;D Lawrence;J L Millan.
Proceedings of the National Academy of Sciences of the United States of America (1986)

511 Citations

Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.

D J Loskutoff;J A van Mourik;L A Erickson;D Lawrence.
Proceedings of the National Academy of Sciences of the United States of America (1983)

509 Citations

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke

Enming J Su;Linda Fredriksson;Melissa Geyer;Erika Folestad.
Nature Medicine (2008)

422 Citations

Familial dementia caused by polymerization of mutant neuroserpin

Richard L. Davis;Antony E. Shrimpton;Peter D. Holohan;Charles Bradshaw.
Nature (1999)

402 Citations

Platelet-derived Growth Factor (PDGF)-induced Tyrosine Phosphorylation of the Low Density Lipoprotein Receptor-related Protein (LRP) EVIDENCE FOR INTEGRATED CO-RECEPTOR FUNCTION BETWEEN LRP AND THE PDGF

Elena Loukinova;Sripriya Ranganathan;Sergey Kuznetsov;Natalia Gorlatova.
Journal of Biological Chemistry (2002)

347 Citations

Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.

Grainne A. McMahon;Eric Petitclerc;Steingrimur Stefansson;Elizabeth Smith.
Journal of Biological Chemistry (2001)

341 Citations

Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis.

Manuel Yepes;Manuel Yepes;Manuel Yepes;Maria Sandkvist;Maria Sandkvist;Maria Sandkvist;Mike K.K. Wong;Timothy A. Coleman;Timothy A. Coleman;Timothy A. Coleman.
Blood (2000)

338 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Daniel A. Lawrence

Peter A. Andreasen

Peter A. Andreasen

Aarhus University

Publications: 91

David A. Lomas

David A. Lomas

University College London

Publications: 84

Paul Declerck

Paul Declerck

KU Leuven

Publications: 80

David J. Loskutoff

David J. Loskutoff

Scripps Research Institute

Publications: 64

Dudley K. Strickland

Dudley K. Strickland

American Red Cross

Publications: 58

Robert L. Medcalf

Robert L. Medcalf

Monash University

Publications: 57

Joachim Herz

Joachim Herz

The University of Texas Southwestern Medical Center

Publications: 36

Steven L. Gonias

Steven L. Gonias

University of California, San Diego

Publications: 36

Paul J. Higgins

Paul J. Higgins

Albany Medical Center Hospital

Publications: 36

Peter Carmeliet

Peter Carmeliet

KU Leuven

Publications: 34

Toshio Miyata

Toshio Miyata

Tohoku University

Publications: 34

Peter G. W. Gettins

Peter G. W. Gettins

University of Illinois at Chicago

Publications: 33

Robin W. Carrell

Robin W. Carrell

University of Cambridge

Publications: 33

Douglas E. Vaughan

Douglas E. Vaughan

Northwestern University

Publications: 32

Manfred Schmitt

Manfred Schmitt

Technical University of Munich

Publications: 31

Desire Collen

Desire Collen

KU Leuven

Publications: 31

Trending Scientists

Ryutarou Ohbuchi

Ryutarou Ohbuchi

University of Yamanashi

Gabriel L. Suciu

Gabriel L. Suciu

United Technologies (United States)

Jonathan D. Albert

Jonathan D. Albert

E Ink (South Korea)

Edward J. Davison

Edward J. Davison

University of Toronto

Gopalan Rajaraman

Gopalan Rajaraman

Indian Institute of Technology Bombay

Yong Liu

Yong Liu

Central South University

Gerco C. Angenent

Gerco C. Angenent

Wageningen University & Research

Tatsushi Toda

Tatsushi Toda

University of Tokyo

Shabtai Cohen

Shabtai Cohen

Agricultural Research Organization

Ying-Jin Yuan

Ying-Jin Yuan

Tianjin University

Xin-Yun Huang

Xin-Yun Huang

Cornell University

Leila M. V. Carvalho

Leila M. V. Carvalho

University of California, Santa Barbara

Rosemary D. Higgins

Rosemary D. Higgins

George Mason University

Emma Renold

Emma Renold

Cardiff University

Tom Cox

Tom Cox

University of Nottingham

Something went wrong. Please try again later.